Matthew Davidson
Chief Development Officer and Director (CEO appointment pending stockholder vote September 17, 2026), ADIAL PHARMACEUTICALS, INC. · United States
Matthew Davidson is the CEO of ADIAL PHARMACEUTICALS, INC. (ADIL). Davidson is based in the United States.
Dr. Matthew Davidson is co-founder and former CEO of Azora Therapeutics. He joined Adial Pharmaceuticals in June 2026 as Chief Development Officer and Director following Adial's acquisition of Azora. He holds a degree from Stanford University School of Medicine.
Recent developments
AI summary of recent coverageRecent coverage of Adial Pharmaceuticals has focused on significant leadership transitions at the company, including plans to replace both the Chief Executive Officer and Chief Financial Officer following the 2026 annual meeting. Earlier reporting also covered the company's expansion of its executive leadership team alongside the completion of a private investment in public equity financing round.
Summarized from the headlines below; see each source for the full story.
Our coverage
On CEOInsider
No feature yet. When we publish a feature, interview or cover story on Matthew Davidson, it will appear here — and tie into the news timeline.
Matthew Davidson: FAQ
- Who is Matthew Davidson?
- Matthew Davidson is the Chief Development Officer and Director (CEO appointment pending stockholder vote September 17, 2026) of ADIAL PHARMACEUTICALS, INC., based in United States.
- What company does Matthew Davidson lead?
- Matthew Davidson is CEO of ADIAL PHARMACEUTICALS, INC..